Arcturus Therapeutics (NASDAQ:ARCT) Issues Earnings Results

Arcturus Therapeutics (NASDAQ:ARCT) released its quarterly earnings data on Monday. The biotechnology company reported ($0.52) EPS for the quarter, topping analysts’ consensus estimates of ($1.58) by $1.06, Zacks reports. Arcturus Therapeutics had a negative net margin of 36.39% and a negative return on equity of 22.39%. The firm had revenue of $29.38 million during the quarter, compared to analysts’ expectations of $25.64 million.

Arcturus Therapeutics Trading Up 2.3%

NASDAQ:ARCT opened at $11.86 on Wednesday. The stock has a market cap of $321.66 million, a P/E ratio of -5.34 and a beta of 2.36. The stock’s 50-day moving average is $11.78 and its 200-day moving average is $15.38. Arcturus Therapeutics has a 1-year low of $8.04 and a 1-year high of $45.00.

Wall Street Analyst Weigh In

ARCT has been the subject of a number of research reports. BTIG Research set a $48.00 target price on Arcturus Therapeutics and gave the stock a “buy” rating in a report on Monday, March 10th. Canaccord Genuity Group dropped their price target on Arcturus Therapeutics from $68.00 to $66.00 and set a “buy” rating for the company in a research note on Tuesday. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arcturus Therapeutics in a research note on Friday, March 7th. Wells Fargo & Company dropped their price target on Arcturus Therapeutics from $58.00 to $50.00 and set an “overweight” rating for the company in a research note on Friday, March 7th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $60.00 price target on shares of Arcturus Therapeutics in a research note on Thursday, April 10th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $58.80.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.